Development and Regulatory Milestones. In partial consideration for the rights granted under this Agreement regarding the Collaboration Products, in each case upon initial achievement of the applicable milestone by or on behalf of SGEN or its Sublicensees for each Collaboration Product, SGEN will pay PIRS the corresponding non-refundable (subject to Section 4.4.2.2) and non-creditable lump sum payments set forth below. Development Event [***] [***] [***] [***] [***] Dollars ($[***]) [***] [***] Initiation of Phase 1 Clinical Study [***] Dollars ($[***]) Initiation of Phase 2a Clinical Study or Initiation of Phase 1 Clinical Study Expansion Cohorts (whichever comes first) [***] Dollars ($[***]) Initiation of Pivotal Clinical Study [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***]) [***] filing with [***] [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***]) [***] filing with [***] [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***]) [***] filing in [***] [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***]) Marketing Approval in the [***] [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***]) Marketing Approval in the [***] [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***]) Marketing Approval in [***] [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***]) Maximum Total [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***])
Appears in 1 contract
Sources: License and Collaboration Agreement (Pieris Pharmaceuticals, Inc.)
Development and Regulatory Milestones. In partial consideration for the rights granted under this Agreement regarding the Collaboration Products, in each case upon initial achievement of the applicable milestone by or on behalf of SGEN or its Sublicensees for each Collaboration Product, SGEN will pay PIRS the corresponding non-refundable (subject to Section 4.4.2.2) and non-creditable lump sum payments set forth below. Development Event [***] [***] [***] [***] [***] Dollars ($[***]) [***] [***] Initiation of Phase 1 Clinical Study [***] Dollars ($[***]) Initiation of Phase 2a Clinical Study or Initiation of Phase 1 Clinical Study Expansion Cohorts (whichever comes first) [***] Dollars ($[***]) Initiation of Pivotal Clinical Study [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***]) [***] filing with [***] [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***]) [***] filing with [***] [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***]) [***] filing in [***] [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***]) Marketing Approval in the [***] [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***]) Marketing Approval in the [***] [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***]) Marketing Approval in [***] [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***]) Maximum Total [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***])
Appears in 1 contract
Sources: License and Collaboration Agreement (Pieris Pharmaceuticals, Inc.)
Development and Regulatory Milestones. In partial consideration for the rights granted under this Agreement regarding the Collaboration Products, in each case upon initial achievement of the applicable milestone by or on behalf of SGEN or its Sublicensees for each Collaboration Product, SGEN will pay PIRS the corresponding non-refundable (subject to Section 4.4.2.2) and non-creditable lump sum payments set forth below. Development Event [***] [***] [***] [***] Go/No-Go DP [***] Dollars ($[***]) [***] [***] Initiation of Phase 1 Clinical Study [***] Dollars ($[***]) Initiation of Phase 2a Clinical Study or Initiation of Phase 1 Clinical Study Expansion Cohorts (whichever comes first) [***] Dollars ($[***]) Initiation of Pivotal Clinical Study [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***]) [***] filing with [***] [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***]) [***] filing with [***] [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***]) [***] filing in [***] [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***]) Marketing Approval in the [***] [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***]) Marketing Approval in the [***] [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***]) Marketing Approval in [***] [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***]) Maximum Total [***] Dollars ($[***]) [***] Dollars ($[***]) [***] Dollars ($[***])
Appears in 1 contract
Sources: License and Collaboration Agreement (Pieris Pharmaceuticals, Inc.)